Your AI-Trained Oncology Knowledge Connection!
Raajit Rampal, MD, is director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center
Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss how the combination of the BET inhibitor pelabresib and the JAK inhibitor ruxolitinib led to greater reductions in spleen size and symptoms compared to ruxolitinib alone in JAK inhibitor-naïve patients with intermediate- or high-risk myelofibrosis in the MANIFEST and MANIFEST-2 trials, with an acceptable safety profile, providing evidence that targeting multiple inflammatory pathways could lead to better disease control.
Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss how JAK inhibitors have reduced spleen size (splenomegaly) and constitutional symptoms like fatigue and fever in patients with myelofibrosis but that there is still room for improvement in treating other aspects of the disease like anemia and bone marrow fibrosis. They also share insights about the potential for combination therapies that target multiple pathways.
Raajit K. Rampal, MD, PhD, presents data from the MANIFEST-2 study investigating pelabresib in combination with ruxolitinib in Janus kinase inhibitor treatment–naïve patients with myelofibrosis.
Raajit K. Rampal, MD, PhD, discusses findings from the phase 3 MANIFEST-2 trial investigating pelabresib in combination with ruxolitinib for JAK inhibitor–naive patients with myelofibrosis.
The panel closes their discussion by highlighting novel agents in the treatment of myeloproliferative neoplasms to look out for.
The panel explains the standards for symptom assessment in patients with myelofibrosis and how often patients are monitored.
Abdulraheem Yacoub, MD, details the side effect profiles of the approved JAK inhibitors for myelofibrosis treatment.
Dr Jamile Shammo discusses how to approach sequencing therapies in patients with myelofibrosis and Dr Raajit Rampal explains the potential of the JAK inhibitor momelotinib in the treatment of myelofibrosis.
Raajit Rampal, MD, and Abdulraheem Yacoub, MD, review data on the use of pacritinib and fedratinib in patients with myelofibrosis.
Jamile Shammo, MD, comments the currently approved treatment options for patients with myelofibrosis and review data from the COMFORT-I and COMFORT-II trials, which evaluates the use of ruxolitinib in MF.
Dr Abdulraheem Yacoub explains allogeneic hematopoietic cell transplantation in myelofibrosis, the only known curative treatment modality.
The panel reviews the types of myelofibrosis, discusses how to risk stratify and explains the role of biomarker testing in patients with MF.
Dr Jamile Shammo reviews recent data on the treatment of patients with polycythemia vera with ropeginterferon.
Abdulraheem Yacoub, MD, reviews data from the RESPONSE and RESPONSE-2 trials on the use of ruxolitinib for the treatment of polycythemia vera.
Jamile Shammo, MD, explains how she decides on the most appropriate treatment option for a patient with polycythemia vera.
Drs Rampal and Yacoub details the currently available treatment options and reviews the rationale for use in patients with PV.
Dr Jamile Shammo describes how risk is assessed for patients with polycythemia vera.
Experts provide an overview of myeloproliferative neoplasms, including the subtypes, process of diagnosis as well as reviewing the role of biomarkers.
Raajit K. Rampal, MD, PhD, discusses how the role of JAK inhibitors will continue to evolve in the treatment of patients with myelofibrosis.
Raajit K. Rampal, MD, PhD, discusses the importance of clinical trial enrollment in patients with myelofibrosis.
Raajit K. Rampal, MD, PhD, discusses the future research of CDK4/6 inhibitors in myeloproliferative neoplasms.
Raajit K. Rampal, MD, PhD, discusses the investigation of pelabresib with or without ruxolitinib in patients with myelofibrosis.
Raajit K. Rampal, MD, PhD, discusses the investigation of ACVR1 inhibition as a mechanism for improving anemia in patients with myelofibrosis.
Raajit K. Rampal, MD, PhD, discusses the potential utilization of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.
Raajit K. Rampal, MD, PhD, discusses the investigation of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.
Raajit K. Rampal, MD, PhD, discusses the importance of risk stratification in myelofibrosis.
Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis.
Raajit K. Rampal, MD, PhD, discusses symptoms of disease progression in myelofibrosis.
Raajit K. Rampal, MD, PhD, discusses considerations for selecting among the JAK inhibitors ruxolitinib and fedratinib in the treatment of patients with myelofibrosis.
Raajit K. Rampal, MD, PhD, discusses the evolution of prognostic models in essential thrombocythemia.
